** Shares of medical test kit maker Myriad Genetics MYGN.O fall ~3% to $13.27
** MYGN says it expects Q4 rev. to be between $209 mln and $211 mln, below analyst estimates of $212.9 mln - data compiled by LSEG
** Co expects Q4 adj. EPS to be between 3 cents and 4 cents vs. analyst est. of 3 cents
** Co forecasts 2025 rev. to be between $840 mln and $860 mln below analyst est. of $876.7 mln
** Co forecasts 2025 adj. EPS to be between 7 cents and 11 cents vs. analyst est. of 8 cents
** 6 of 16 brokerages rate the stock "buy" or higher, 6 "hold" and 4 "sell" or lower; their median PT is $20.50 - LSEG
** MYGN fell 27.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。